Naslov
A COMPREHENSIVE PHARMACOGENOMIC MULTI-GENE PANEL ANALYSIS IN CLINICAL PRACTICE, EXPERIENCE FROM ST. CATHERINE HOSPITAL

Autori
Vid, Matišić ; Petar, Brlek ; Vilim, Molnar ; Eduard, Pavelić ; Martin, Čemerin ; Kristijan, Vrdoljak ; Andrea, Skelin ; Damir, Erceg ; Davor, Moravek ; Ivana, Erceg Ivkošić ; Dragan, Primorac

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Journal of Bioanthropology / - : Institut za antropologiju, 2022, 126-126

ISBN
978-953-57695-4-5

Skup
The Twelfth ISABS Conference on Forensic and Anthropological Genetics and Mayo Clinic Lectures in Individualized Medicine

Mjesto i datum
Dubrovnik, Hrvatska, 22.06.2022. - 27.06.2022

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
pharmacogenomics, clinical application, adverse drug reactions

Sažetak
The field of pharmacogenomics is still in its early stages. However, multi-gene panelbased pharmacogenomic tests are readily available for both clinicians and patients. In the Republic of Croatia, single-gene testing has been available for over a decade ; however, commercial panel-based tests targeting multiple genes known to influence drug response is a new concept that was implemented in 2018 at St. Catherine Hospital. This cross-sectional study aimed to report the prevalence of actionable pharmacogenetic interventions in patients who had undergone pharmacogenetic testing using the RightMed 27-gene panel. Retrospective analysis of single-center electronic health records was performed, including a total of 319 patients. Patients underwent pharmacogenomic testing by the RightMed panel using a TaqMan quantitative real-time PCR method and copy number variation (CNV) analysis to determine the SNPs in the 27 targeted genes from 2018 until 2022. Actionable drug-gene pairs were found in 235 (73.7%) patients. Relevant guidelines on genotypebased prescribing were available for 133 (56.7%) patients at the time of testing. Based on the patients’ genotype, 139 (43.6%) patients were using at least one drug with significant pharmacogenetic interactions, potentially predisposing them to adverse drug reactions or lack of therapeutic response. Two out of three patients in our practice were found to have at least one gene-drug interaction ; therefore, the next step in personalized medicine is integrating pharmacogenomic data into patients’ electronic health records to optimize drug therapy.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA